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Abstract
Objective The purpose of this article is to provide a compre-
hensive review of the role of imaging modalities other than
PET/CT in the management of Hodgkin lymphoma (HL).
PET/CT is the imaging modality of choice in the management
of Hodgkin’s lymphoma (HL). However, imaging modalities
other than PET/CT such as plain radiographs, ultrasound, CT,
MRI and nuclear imaging can help in various stages of clinical
management of HL, including the initial workup and post-
treatment surveillance. Both CT and MRI help in detecting
recurrences, treatment-related pulmonary, cardiovascular and
abdominal complications as well as second malignancies. Fa-
miliarity with expected post-treatment changes and complica-
tions on surveillance images can help radiologists guide pa-
tient management. The purpose of this article is to provide a
comprehensive review of the role of imaging modalities other
than PET/CT in the management of Hodgkin lymphoma
(HL).
Main Messages
• Surveillance of HL patients is usually performed with plain
radiographs and CT.
• Follow-up imaging can depict normal post-treatment chang-
es or treatment-related complications.
• Imaging is important for the timely detection of second ma-
lignancies in HL patients.
Keywords Hodgkin lymphoma . PET/CT . Computed
tomography .MRI ultrasound
Introduction
Hodgkin lymphoma (HL) accounts for approximately 10 % of
all lymphomas diagnosed in the developed world annually [1].
The WHO classification divides HL into two main types: clas-
sical HL (CHL) and nodular lymphocyte predominance HL
(NLPHL). CHL is further subdivided into four histological
subtypes: nodular sclerosis CHL (NSCHL), mixed cellularity
CHL (MCCHL), lymphocyte-rich CHL (LRCHL) and
lymphocyte-depleted CHL (LDCHL) [2]. HL has bimodal
age distribution with most patients diagnosed between 15
and 30 years of age, followed by another peak in adults over
the age of 50. HL is usually confined to the lymph nodes.
Cervical and mediastinal lymph nodes are the most common
site of lymph nodal involvement in HL. In mediastinal lymph
nodes, prevascular and paratracheal subsets are most common-
ly affected. Isolated infradiaphragmatic lymphadenopathy oc-
curs in less than 10 % of patients at diagnosis [3]. Extranodal
involvement is less common in HL than in NHL and seen in
only 10–15%of patients. Themost frequent sites of extranodal
involvement are bone, bone marrow, lung and liver [4].
HL is now curable in more than 80 % of cases owing to
significant therapeutic advances in the form of newer chemo-
therapeutic drugs, advances in radiotherapy and stem cell
transplantation [5]. Treatment for HL usually depends on the
stage at diagnosis, histological subtype and prognostic factors.
According to National Comprehensive Cancer Network
(NCCN) guidelines, the initial evaluation of patients with
HL includes detailed history and physical examination, eval-
uation of performance status, laboratory investigations (blood
counts, ESR, LDH, liver and renal function tests) and
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radiological investigations (chest radiograph, PET/CT,
contrast-enhanced CT). Staging for HL is based on the Cots-
wolds modification of the Ann Arbor staging system.
Patients with HL are usually classified into four groups:
early-stage favourable (stage I–II with no unfavourable fac-
tors), early-stage unfavourable (grade I–II with any of the
unfavourable factors), advanced favourable (clinical stage III
or IV with zero to three adverse risk factors listed below) and
advanced unfavourable (clinical stage III or IV with four or
more adverse risk factors listed below). Large mediastinal
adenopathy (>33 % of the thoracic width on the chest x-ray,
≥10 cm on CT), presence of B symptoms, more than 2 or 3
nodal sites of disease or an ESR of 50 or more are
unfavourable prognostic factors for patients with stage I and
II disease. Assessment of prognosis is important for formulat-
ing management strategies.
For patients with advanced-stage HL, the International
Prognostic Factors Project has developed an International
Prognostic Index with a prognostic score that is based on the
following seven adverse factors: age more than 45 years, male
gender, stage IV disease, albumin level below 4.0 g/dl,
haemoglobin level below 10.5 g/dl, white blood cell count
more than 15,000/mm³, absolute lymphocytic count less than
600/mm³ or a lymphocyte count less than 8 % of the total
WBC count [6].
Chemotherapy or combination chemotherapy plus low
dose involved field radiation therapy (LD-IFRT) is the stan-
dard treatment option in HL. The most common chemothera-
peutic regimes used for HL are ABVD (doxorubicin,
bleomycin, vinblastine, dacarbazine), Stanford V (doxorubi-
cin, vinblastine, mechlorethamine, vincristine, bleomycin,
etoposide and prednisone) and BEACOPP (bleomycin,
etoposide, doxorubicin, cyclophosphamide, vincristine, pro-
carbazine and prednisone). Patients with nonbulky stage IA
or IIA disease are considered to have clinical early-stage dis-
ease. These patients are candidates for chemotherapy, com-
bined modality therapy or radiation therapy alone [7]. The
number of cycles is determined by the pre-treatment prognos-
tic factors (favourable or unfavourable disease) and the rate of
response to treatment. The treatment for HL also depends on
the patient’s performance state and the response to treatment.
ABVD, Stanford V or escalated BEACOPP is the preferred
therapy for patients with advanced HL. For patients with re-
fractory HL or who relapse after chemotherapy and
involved-field radiation therapy, second-line chemother-
apeutic agents, biological therapy (such as rituximab)
and autologus stem cell transplant are treatment options.
The role of consolidation radiotherapy after chemother-
apy in patients with advanced HL is controversial; how-
ever involved-field radiotherapy (IF-RT) is beneficial for
patients with partial response after chemotherapy ac-
cording to a prospective randomised trial of 739 patients
with advanced HL [8].
Due to improved long-term survival, treatment-related
complications have emerged as an important cause of morbid-
ity and mortality in patients with HL. Early and accurate di-
agnosis of treatment-related cardiovascular and pulmonary
complications and second malignancies are of paramount im-
portance to continue the survival benefit in these patients,
especially in those treated with mantle field radiation.
Imaging, especially PET/CT, plays a key role in the diag-
nosis, staging, response assessment, prognostication and sur-
veillance of patients with HL. Though FDG-PET/CT is the
imaging modality of choice in HL, other modalities such as
conventional radiographs, ultrasound (US), CT and magnetic
resonance imaging (MRI) are often used in the evaluation of
lymphoma at various stages of management. In this article, we
review the role of various imaging modalities beyond FDG-
PET/CT in the management of HL with emphasis on imaging
features of treatment-related complications.
PET/CT in Hodgkin’s Lymphoma
According to NCCN, 18 F-Fluoro-DeoxyGlucose (FDG) pos-
itron emission tomography (PET)/computed tomography
(CT) is the corner stone for initial staging and evaluation of
treatment response in HL. Response to treatment with chemo-
therapy or combinedmodality therapy is assessed by restaging
with FDG-PET/CT at midcycle (interim PET/CT) or comple-
tion of treatment. FDG-PET positivity at the treatment com-
pletion is an adverse prognostic factor for disease-free survival
[9]. Metabolic imaging with PET often leads to either
upstaging or downstaging in approximately 15–40 % of pa-
tients with Hodgkin lymphoma with impact on management
in about 5–15 % [10, 11]. Several studies have established the
role of interim FDG-PET in the prognosis of HL during che-
motherapy. PET is particularly useful in the evaluation of a
post-treatment residual mass in patients after the completion
of therapy, with positive FDG-PET associated with a signifi-
cantly poorer progression-free survival [12]. Negative interim
FDG-PET/CT is highly predictive of progression-free surviv-
al, even more than the International Prognostic Score (IPS)
[13, 14]. According to a prospective study, the sensitivity
and specificity of FDG PET to predict relapse are 79 % and
97 %, respectively, with a negative predictive value more than
90 % in HL patients after the completion of chemotherapy
[15]. Negative PET study reliably rules out disease relapse.
However, the positive predictive value of PET is variable,
which is an important limitation of PET, and a biopsy is nec-
essary to confirm the diagnosis of a relapse [16]. FDG-PET/
CT is also useful in radiation treatment planning and helps in
better delineation of the radiation field without increasing ra-
diation volumes [17]. There are some important limitations of
FDG-PET/CT. FDG uptake can also be seen in post-treatment
inflammation, infection, brown fat and normal physiologic
382 Insights Imaging (2015) 6:381–392
metabolic activity, which can lead to false-positive results.
Similarly, low-grade histological subtypes and minimal resid-
ual disease can give false-negative results.
Imaging beyond PETat initial staging
The most typical presentation of HL is painless, enlarged su-
perficial lymphadenopathy with systemic symptoms such as
fever, night sweats, fatigue and weight loss. Patients with in-
trathoracic lymphadenopathy may present with respiratory
symptoms such as cough, dyspnoea and chest pain. Chest
radiography can be performed as the initial investigation in
these patients. Chest X-ray provides preliminary information
about involvement of the mediastinum and lungs. Bulky me-
diastinal lymphadenopathy at diagnosis is an unfavourable
prognostic factor in patients with HL and can be quantified
by measuring using the mediastinal mass ratio. Cotswolds
modification of the Ann Arbor staging system defines bulky
disease as a mediastinal mass exceeding one third of the in-
ternal transverse diameter of the thorax at the T5/6 interverte-
bral disc level on a posteroanterior chest radiograph (Fig. 1)
[18]. US is often helpful in confirming enlarged nodes and
guiding biopsy, particularly cervical lymph nodes, the most
common nodal group affected in patients with HL. US
can be useful for evaluation of extranodal sites of in-
volvement in the abdomen (e.g., gallbladder, kidney)
and image-guided biopsy of focal lesions in solid organs
such as the liver and spleen [19].
CT can be performed for further evaluation of abnormali-
ties detected on chest x ray. CT can help in depicting other
areas of lymph node enlargement that are not obvious on chest
radiographs. On CT, HL is characterised by the presence of a
discrete anterior mediastinal mass with a lobulated contour
with homogeneous soft-tissue attenuation. Large lymph nodal
masses can have a heterogeneous appearance with low atten-
uation areas representing necrosis, haemorrhage or cystic de-
generation (Fig. 1). CT is particularly useful for exact anatom-
ical delineation of lymph nodal involvement and in formulat-
ing treatment plans and radiation fields.
Although PET/CT remains the corner stone for initial stag-
ing and response assessment at the completion of treatment in
patients with HL,MRI plays an important part in management
of patients with HL. The role of MRI is particularly important
in paediatric and younger patients because of exposure to
ionising radiation in diagnostic modalities such as CT and
PET/CT. In recent years, diffusion-weighted imaging (DWI)
has been emerging as a radiation-free alternative to PET/CT
for staging of various malignancies including lymphoma [20].
DWI is a functional MRI technique that depicts differences in
the mobility of water in tissues. Hypercellular tumours exhibit
more restricted water diffusion than normal tissues, which is
reflected as high signal intensity on DWI with low apparent
diffusion coefficient (ADC) values. DWI-MRI has sensitivity
up to 97 % and is a feasible alternative to PET/CT for follow-
up and treatment response assessment in patients with FDG-
avid lymphoma [21, 22]. The whole body-DWI technique
does not need specific equipment and is well tolerated by
patients thanks to the relatively shorter acquisition time, which
is longer than the acquisition time for CT but shorter than for
PET/CT. The use of higher magnetic field strength (3 T) has a
higher signal-to-noise ratio (SNR), which improves the ability
of lesion detection. The cost of a WB-MRI is roughly equal to
the cost for an 18F-FDG PET/CT examination. MRI is also
useful in evaluation of intracranial disease and spinal cord
involvement because of better soft tissue resolution. In the
thorax, MRI is beneficial for assessment of chest wall, vascu-
lar, cardiac and pleural and brachial plexus involvement [23].
Central venous thrombosis and compression: Superior ve-
na cava (SVC), brachiocephalic or internal jugular veins can
be directly compressed by the mediastinal adenopathy with
development of SVC syndrome. Lymphoma is responsible
for about 10 % of malignant SVC obstruction cases [24].
SVC and brachiocephalic venous thrombosis can also compli-
cate chemotherapy catheter placement in patients with HL.
Contrast-enhanced chest CT is the modality of choice for
evaluation of SVC obstruction and to differentiate between
venous thrombosis and extrinsic compression. Chest wall ve-
nous collaterals and characteristic focal hyperenhancement of
liver (Bhot-spot sign^) is seen with SVC or brachiocephalic
vein obstruction due to opening of caval-mammary-phrenic–
hepatic capsule-portal pathways (Fig. 1). In this pathway,
blood flows from the internal mammary vein to the inferior
phrenic vein. The inferior phrenic vein then communicates
with hepatic capsular veins, which in turn drain into
the intrahepatic portal tributaries. Focal non-mass-like
contrast enhancement is seen along the superior aspect
of the liver with dilated inferior phrenic veins and he-
patic capsular veins [25, 26].
Central nervous system (CNS) involvement in HL is rare
with an overall reported incidence of 0.2–0.5 % [27]. Intracra-
nial HL is usually seen in patients with relapsed and progres-
sive disease as a part of widespread systemic involvement.
The most common histological subtypes of CHL associated
with CNS involvement are MCHL and NSHL. Evaluation of
CNS involvement in HL on FDG-PET is limited by the in-
tense physiologic FDG uptake in the brain. CT with intrave-
nous contrast and MRI are useful in such instances. Spinal
cord compression is a rare complication of HL, occurring
usually in the setting of progressive and advanced disease.
As the initial symptom of HL, it is extremely rare, with only
a few cases reported in the literature [28]. Prompt diagnosis is
crucial as early surgical decompression, radiation therapy and
chemotherapy are imperative to prevent irreversible neu-
rological deficits. MR imaging of the spine, without and
with the use of gadolinium-based contrast material, is
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the standard for the diagnosis of malignant spinal cord
compression (Fig. 2) [29].
Imaging beyond PET during follow-up
Due to the long-term risks and complications of the therapies
of HL, regular follow-up of treated patients with HL is impor-
tant. The follow-up schedule depends on the age of patients,
staging at the time of diagnosis and type of treatment given.
Physical examinations and blood tests are performed every 3
to 6 months for the first 2 years, then every 6 to 12 months for
the next 3 years and then annually [30]. The NCCN guidelines
recommend imaging techniques such as chest radiographs or
chest CT and abdomen and pelvis CT to be performed every
6 months for the first 2 years and then annually for the next
3 years. If the neck is involved in the radiation treatment field,
thyroid function tests are performed annually. The overall 5-
year survival rate for early-stage HL in children and
adolescent population is more than 90 % [31]. However, up
to 10 % of patients with early-stage and up to 25 % patients
with advanced-stage HL relapse after first-line therapy [32]. In
addition to detecting long-term treatment-related complica-
tions, the goal of the surveillance scans is to detect local and
distant recurrences of lymphoma. Recurrent lymphoma has
the same appearance as primary HL; however pulmonary pa-
renchymal involvement is more common in recurrent HL. The
various patterns of parenchymal involvement include a pul-
monary nodule or mass, lobar or segmental consolidation with
an air bronchogram and a ret icular pat tern with
peribronchovascular and interlobular septal thickening [33].
Findings suggestive of recurrent disease in the radiation field
include an alteration in the contour of the radiation fibrosis
with an increase in size, convex borders, appearance of homo-
geneous opacity with obliteration of the air bronchogram and
filling of the bronchi (Fig. 3) [34].
Restaging CTexaminations often demonstrate findings that
represent expected post-treatment changes. Dystrophic lymph
Fig. 1 A 39-year-old male with increasing cough, night sweats and
weight loss since 2 months. a Frontal chest radiograph demonstrates
bulky mediastinal lymphadenopathy exceeding one third of the internal
transverse diameter of the thorax. b Axial contrast-enhanced CT image
reveals large conglomerate anterior mediastinal lymph nodal mass
(arrow) and right-sided pleural effusion (arrowhead). Biopsy of lymph
nodal mass was suggestive of nodular sclerosing HL. Follow-up CTstudy
after treatment with chemotherapy and mediastinal radiation complicated
by chronic venous thrombosis. c Coronal contrast-enhanced CT image
shows focal hyperenhancement (arrow) in segment IVof the liver due to
reflux in a capsular vein (arrowhead) communicating with the inferior
phrenic vein (not shown). d Axial contrast-enhanced CT image
demonstrates chronic occlusion of the left brachiocephalic vein (arrow)
with multiple chest wall and paravertebral venous collaterals on the left
side (arrowheads)
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nodal calcification is seen in approximately 2–8 % of treated
patients with HL following radiation or chemotherapy
(Fig. 4). Lymph nodal calcification in untreated patients is
seen in less than 1 % of patients with aggressive histological
subtypes of HL [35]. In treated patients, dystrophic calcifica-
tion represents treatment-induced necrosis and is associated
with good prognosis and long-term survival [36]. Absence
of spleen is another finding on imaging that can be encoun-
tered in patients with HL. Before effective chemotherapy and
radiotherapy were available and staging was crucial to differ-
entiate limited-stage disease from extensive-stage disease,
splenectomy was often performed in patients with HL as
20–35 % with clinically limited disease confined to above
the diaphragm will have occult splenic involvement [37].
Rebound hyperplasia of the thymus occurs in 10 to 25% of
patients treated with chemotherapy [38]. Thymic rebound
usually occurs 1 to 11 months after completion of chemother-
apy because of reactive lymphoid hyperplasia in response to
withdrawal of chemotherapy and is usually self-limiting and
reversible [39]. It is important to differentiate thymic rebound
from recurrent mediastinal disease. CT features that favour
thymic regrowth over lymphomatous thymic involvement or
thymic tumour are a diffusely enlarged thymus that maintains
the normal thymic morphology with a smooth contour, uni-
form density without invasion of adjacent tissues and absence
of pericardial or pleural effusion (Fig. 5).
Until the 1990s in the prechemotherapy era, radiation ther-
apy was often used as a single modality in the treatment of HL
with more extended fields and higher doses than in current
radiotherapy techniques [40]. In patients who have received
infradiaphragmatic radiotherapy, various abdominal organs
could be affected by side effects of radiation. Radiation-
induced liver disease (radiation hepatitis) has a threshold of
30–35 Gy for the whole liver. Radiation-induced liver injury
demonstrates an acute phase occurring within 3 months of
exposure characterised by hyperaemia, venous congestion
Fig. 2 A 36-year-old male with
newly diagnosed nodular
sclerosing HL presenting with
numbness in his right hand. a
Sagittal contrast-enhanced T1-
weighted image of the cervical
spine demonstrates enhancing
epidural soft tissue (arrow) at the
C4 to C6 vertebral levels. b Axial
contrast-enhanced T1-weighted
image demonstrates epidural
enhancing soft tissue (arrow) with
significant compression and mass
effect on the cervical spinal cord
(arrowhead)
Fig. 3 A 35-year-old male with a history of HL treated 3 years ago with
chemotherapy and mediastinal radiation presenting with relapsed HL in
the radiation field. aAxial CT image in lungwindow settings shows well-
demarcated area of parenchymal distortion and traction bronchiectasis in
a paramediastinal location in the right lower lobe (arrow) suggestive of
post-radiation changes. b Axial CT image in lung window settings after
3 years shows the appearance of a lobulated mass within the radiation
field with obliteration of the previously visualised air bronchogram
(arrow). New appearance of ground-glass opacities with consolidation
(arrowhead) is seen in the right middle lobe
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and fatty infiltration and a chronic phase with development of
fibrosis and architectural distortion. On CT it appears as a
sharply demarcated area of hypodensity corresponding to the
radiation ports; however, in case of background fatty infiltra-
tion of liver, the irradiated area appears hyperdense compared
to adjacent liver parenchyma. Radiation-induced pancreatic
injury is characterised by parenchymal atrophy and fibrosis.
The spleen is also radiosensitive and splenic atrophy occurs at
doses of 35–40 Gy [41]. The upper poles of the kidneys (more
commonly the left kidney because of its higher anatomical
position than the right) can be affected by radiation.
Radiation-induced cortical thinning and atrophy of the upper
poles of the kidneys are well demarcated from the rest of the
renal parenchyma and frequently seen on follow-up studies in
patients with HL (Fig. 6) [42]. Uncommonly, lymphomatous
involvement in the abdomen and pelvis can fistulise with the
gastroitestinal tract resulting in tumour-bowel fistula (TBF).
TBF can occur either spontaneously or following treatment
with radiotherapy or chemotherapy. Gastrosplenic fistula can
occur in association with gastric or splenic lymphoma and
clinically manifests with epigastric pain and upper gastroin-
testinal bleeding [43, 44]. CT is the investigation of choice for
the diagnosis of TBF with demonstration of a tract following
oral contrast administration (Fig. 7).
Radiation therapy causes destruction of haematopoietic
marrow elements and their replacement by fatty marrow ele-
ments usually occurring 3 to 6 weeks following radiotherapy;
this is characterised by fatty replacement of marrow and man-
ifests on MRI as T1 hyperintensity with a sharp demarcation
corresponding to the radiation port [45]. Bone marrow recov-
ery after radiation therapy can be reversible or irreversible
depending on the amount of radiation given. Partial or com-
plete recovery usually occurs at low doses (less than 30 Gy).
Permanent fatty marrow replacement is usually seen above the
dose of 36 Gy with very little chance of complete recovery
[46].
Complications of treatment
The main cause of increased mortality and morbidity among
long-term survivors of HL are treatment-related development
of secondary cancers, drug-related toxicities, radiation-
induced pulmonary, cardiovascular and abdominal complica-
tions, thyroid disorders and myelosuppresion.
Cardiovascular toxicity Cardiovascular toxicity in treated
patients with HL can be due to doxorubicin and/or radiation.
The cause-specific mortality for cardiovascular disease is ap-
proximately 10 % [47]. The cumulative incidence of adverse
cardiac events in patients treated for HL is more than 20 %
25 years after radiotherapy and prior mediastinal radiation is a
long-term risk factor for increased cardiovascular mortality
and morbidity in HL patients, especially with doses above
30 Gy [48, 49]. Radiation produces dose-dependent cardiac
damage through several different mechanisms. Radiation-
induced cardiovascular complications can be acute, such as
acute pericarditis, or chronic, such as coronary artery disease,
valvular heart disease, decreased ventricular function, arrhyth-
mia and chronic pericarditis. Initial evaluation of coronary
artery disease is done with stress echocardiography or nuclear
scintigraphy to look for inducible ischaemia. Patients with a
Fig. 4 A 37-year-old male with a history of HL treated with
chemotherapy and mediastinal radiation 5 years ago. Axial contrast-
enhanced CT image reveals anterior mediastinal lymphadenopathy with
peripheral calcification (arrows)
Fig. 5 A 22-year-old male with relapsed HL shows thymic rebound after
second-line chemotherapy. a Axial non-contrast CT image shows
triangular low-attenuation anterior mediastinal soft tissue (arrow)
suggestive of normal thymus. b Axial non-contrast CT image after
3 months of chemotherapy shows diffusely enlarged thymus (arrow).
The thymic contour is maintained with smooth margins and absence of
surrounding vascular invasion. c Axial non-contrast CT image 4 months
after completion of chemotherapy shows resolution of thymic
enlargement with similar appearance of thymus compared to
pretreatment study
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positive stress test can be further evaluated with coronary CT
angiography. Coronary calcifications are frequently visualised
at follow-up chest CT in patients with treated HL (Fig. 8).
Patients treated with radiation therapy are also at higher risk
for development of noncoronary arteriosclerotic vascular dis-
ease including subclavian and carotid artery stenosis (Fig. 8).
In a retrospective study of 414 patients treated with radiation
therapy, Hull et al. found the incidence of noncoronary ath-
erosclerotic disease was 2% at 5, 3% at 10 and 7% at 20 years
[50]. Radiation-induced pericardial disease can manifest in the
form of pericarditis or pericardial effusion and is seen in 20 to
40% of patients treated with mantle field radiation [51]. Echo-
cardiography andMRI are useful modalities for the evaluation
of pericardial disease. Radiation-induced valvular disease can
manifest as both stenosis and insufficiency.
Anthracyclines cause dose-dependent cardiac toxicity that
can produce irreversible cardiomyopathy. Left ventricular
dysfunction has been reported to occur in 5 % of patients at
cumulative doses as low as 240 mg/m2 [52]. Monitoring of
left ventricular function with echocardiography, radionuclide
angiography or less commonly cardiac MRI is recommended
in patients who have received anthracycline-based chemother-
apy. A multiple-gated acquisition (MUGA) scan is particular-
ly useful for determination of the ejection fraction in HL pa-
tients before and after they undergo chemotherapy. A 10 %
decline of the left ventricular ejection fraction (LVEF) below
the lower limit of normal or an absolute decline of 45 % or
decline of 20 % at any level is indicative of cardiac function
deterioration. The risk of cardiac toxicity increases with com-
bined treatment (doxorubicin and radiation) compared to ei-
ther treatment given alone [48, 53, 54].
Pulmonary toxicity Like cardiovascular toxicity, pulmonary
toxicity in HL patients can be due to radiotherapy or cytotoxic
chemotherapy.
Radiation-induced pulmonary toxicity Newer radiotherapy
techniques such as involved-site radiation therapy (ISRT) and
intensity-modulated radiation therapy (IMRT) deliver less ra-
diation to uninvolved normal organs compared to convention-
al involved-field or extended-field radiation therapy and re-
duce the long-term pulmonary and cardiovascular toxicity
[55]. The degree of radiation damage depends on multiple
factors such as the total radiation dose, fractionation, dose rate,
volume of the lungs receiving a specified dose and beam ar-
rangement [56].
Radiologic manifestations are usually confined to the lung
tissue within the radiation port and are dependent on the
Fig. 7 A 49-year-old male with relapsed HL with splenic lesions treated
with second-line chemotherapy. a Coronal contrast-enhanced CT image
shows splenomegaly with multiple low-attenuation splenic lesions
(arrows). b Coronal contrast-enhanced CT image 4 months after
treatment with second-line chemotherapy demonstrates communication
between the stomach and spleen (arrow) with the presence of hyperdense
oral contrast material (arrowhead) and air specs in a low-attenuation
splenic lesion suggestive of gastrosplenic fistula
Fig. 6 A 49-year-old female with a history of nodular sclerosing HL
treated 23 years ago with mantle and paraaortic radiation to a total dose
of 36 Gy. Coronal reformatted image of contrast-enhanced CT shows
cortical thinning of the upper pole of the left kidney (arrow). Note the
absence of spleen from the prior splenectomy
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interval after completion of treatment. Radiation-induced lung
injury is divided into two clinical stages: the early stage
characterised by radiation pneumonitis and late stage
characterised by chronic radiation fibrosis. Early radiation
pneumonitis usually occurs about 4–12 weeks after comple-
tion of radiation therapy and is characterised by ground-glass
opacification, consolidation and atelectasis within the radia-
tion portals. Radiation fibrosis usually develops within 6–
12 months after completion of radiation therapy. Typical fea-
tures of radiation fibrosis include a well-demarked area of
volume loss, linear scarring or consolidation, parenchymal
distortion and traction bronchiectasis, ipsilateral mediastinal
shift and adjacent pleural thickening [34, 57].
Bleomycin- and cyclophosphamide-induced pulmonary
toxicity Bleomycin is commonly used in chemotherapy reg-
imens of HL. Bleomycin-induced lung injury usually occurs
in 3 %–20 % of treated patients [58]. HRCT is more sensitive
than chest radiographs in identifying bleomycin-induced lung
abnormalities. Commonmanifestations of bleomycin-induced
lung disease are diffuse alveolar damage, nonspecific intersti-
tial pneumonia (NSIP) and bronchiolitis obliterans organising
pneumonia (BOOP) (Fig. 9). Cyclophosphamide can cause
pulmonary haemorrhage and diffuse alveolar damage. CT
manifestations of NSIP include patchy ground-glass opacities
combined with reticular opacities in peripheral subpleural dis-
tribution. BOOP is characterised by bilateral asymmetrical
ground-glass opacities or airspace consolidation in a periph-
eral or peribronchial distribution [59, 60].
Second malignancies Second malignancies are the leading
cause of death in long-term survivors of HL. Risk factors
depend on the type of second malignancy and include the
radiation dose and field, chemotherapy agents and doses ad-
ministered, history of smoking and sex and age of the patient
[61]. The maximum risk of a second cancer is at 5 to 9 years
after chemotherapy alone, but after combined modalities the
risk remains for 25 years or longer [62]. Solid tumours ac-
count for more than 50 % of second malignancies developing
after 15 or more years of follow-up in patients treated for HL
[63]. Lung and breast cancers are the most common secondary
cancers in patients with HL due to their proximity to the radi-
ation portal (Fig. 10a) [64]. Other solid tumours that have an
increased incidence among HL survivors include gastrointes-
tinal cancers, bone and soft tissue tumours, thyroid cancers,
malignant melanoma, bladder cancer and malignant mesothe-
lioma. The risk of developing secondary cancer is lower with
combined modality treatment than with radiotherapy alone as
the initial treatment [61, 63, 65, 66].
Fig. 8 Cardiovascular complications. a A 38-year-old female with a
history of nodular sclerosing HL at the age of 12 treated with
chemotherapy and upper mantle radiation. Axial non-enhanced CT
image shows mitral valve calcification (arrow). Note the bilateral
mastectomies with a breast prosthesis from prior breast cancer. b A 40-
year-old female with a history of nodular sclerosing HL at the age of 15
treated with chemotherapy and upper mantle radiation. Digital subtraction
angiogram of the left carotid artery shows moderate to severe narrowing
of the left distal common carotid artery (arrow). c Coronal reformatted
image of contrast-enhanced CT during follow-up shows the presence of a
stent in the left common carotid artery (arrow). Note the presence of
aortic arch and right coronary artery calcifications (arrowheads). Also
note the absence of spleen from the prior splenectomy
Fig. 9 A 22-year-old male with nodular sclerosing HL on treatment with
an ABVD regimen and complaining of new onset cough without fever.
Axial contrast-enhanced lung window CT image shows patchy ground-
glass opacities in the right lower lobe with peripheral subpleural
distribution suggestive of drug toxicity
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The risk of lung cancer is substantially increased in patients
with HL treated with radiotherapy or chemotherapy, especial-
ly among smokers. The overall survival of non-small-cell lung
cancer (NSCLC) in the setting of treated HL is inferior com-
pared to patients with de novo lung cancer [67]. Breast cancers
after HL typically occur after a long latency of 10–15 years
and are associatedwith young age at irradiation. Annual breast
screening (mammography or MRI) beginning no later than 8
to 10 years after treatment completion or at age 40 (whichever
occurs earlier) is recommended for woman who have received
chest or axillary radiation [68].
Patients with HL have a 20-fold increased risk of mesothe-
lioma after radiotherapy. Mesothelioma arises from the meso-
thelial cells forming the serosal membranes of body cavities.
Pleural and peritoneal cavities are frequent sites of involve-
ment. Patients with lymphoma-associated malignant mesothe-
lioma have younger age at diagnosis and longer overall sur-
vival compared with those with asbestos-associated mesothe-
lioma [69]. CT is the primary imaging modality used for the
evaluation of malignant pleural mesothelioma. Pleural
mesothelioma presents as pleural thickening, pleural-based
nodules, pleural effusion, thickening of interlobular fissures
and pleural calcifications. The tumour frequently causes inva-
sion of the chest wall, pericardium, heart and diaphragm.MRI
is particularly helpful in detecting chest wall and mediastinal
involvement because of the improved soft tissue contrast res-
olution [70, 71]. The CT features of malignant peritoneal me-
sothelioma are peritoneal- or omental-based masses as well as
irregular or nodular peritoneal thickening with or without as-
cites (Fig. 10b) [72].
Radiotherapy is the main cause of thyroid cancers after HL,
since the thyroid gland is a highly radiosensitive organ and is
frequently exposed to radiation because of its location in neck
(Fig. 10c). The risk of developing various thyroid abnormal-
ities such as thyroid cancer, Grave’s disease, thyroiditis, hy-
pothyroidism, nodular thyroid disease and thyroid atrophy is
more than 50 % in patients with HL [40, 73, 74].
Patients with HL who received subdiaphragmatic radio-
therapy have a dose-dependent increased risk of gastric can-
cer. The risk is further increased in patients who also received
Fig. 10 Second malignancies in patients with HL. a A 40-year-old
female with a history of nodular sclerosing HL at the age of 15 treated
with chemotherapy and upper mantle radiation. Axial contrast-enhanced
lung window CT image shows a soft tissue mass within the right
paramediastinal radiation field. Pathology was suggestive of
adenocarcinoma of the lung. b A 24-year-old female presenting with
upper abdominal pain and fullness with a prior history of HL at the age
of 13 treated with splenectomy and radiation. Axial non-enhanced CT
image of the upper abdomen shows a soft tissue mass lesion in the left
upper abdomen (arrow). Pathology was suggestive of mesothelioma. c A
48-year-old female with a history of nodular sclerosing HL at the age of
15 treated with chemotherapy, mantle and pelvic radiation. Transverse
greyscale ultrasound image shows a solid nodule in the right lobe of the
thyroid (arrow). Fine-needle aspiration cytology from the nodule was
suggestive of papillary thyroid carcinoma. d A 56-year-old female
presenting with shortness of breath, intermittent cough and weight loss
with a prior history of HL treated with radiation 40 years ago. Axial
contrast-enhanced CT image shows a large heterogeneously enhancing
anterior mediastinal mass (arrow). Pathology was suggestive of radiation-
induced sarcoma
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chemotherapy with MOPP (mechlorethamine, vincristine,
procarbazine and prednisone) or BEACOPP regimes contain-
ing procarbazine. The stomach cancer risk is also increased in
patients who are treated with dacarbazine, a component of the
ABVD regimen, frequently used in patients with HL [75].
Radiation-induced sarcoma (RIS) is rare and associated
with higher doses of radiation and with the use of concurrent
chemotherapy (Fig. 10d). The mean latency period for post-
radiation bone and soft tissue sarcomas ranges from 4 to
17 years [76]. Post-radiation sarcoma usually arises in or near
the radiation field [77].
Imaging plays an important role in the timely detection of
second malignancies in patients with HL. Knowledge of the
history and site of prior radiotherapy can help the radiologists
to increase the index of suspicion of second malignancies.
Conclusion
In conclusion, although PET/CT remains the cornerstone for
initial staging and response assessment at the completion of
treatment in patients with HL, imaging modalities other than
PET/CT often help in the initial workup of patients with HL.
Treatment for HL usually depends upon the stage at diagnosis,
histological subtype and prognostic factors, and chemothera-
py or combination chemotherapy plus low-dose involved-
field radiation therapy (LD-IFRT) is the standard treatment
option in HL. Treatment response is assessed by restaging
PET/CT using the Deauville criteria. Surveillance of HL pa-
tients after treatment is performed with plain radiographs and
CT. Follow-up imaging can depict normal post-treatment
changes or complications including second malignancies. Fa-
miliarity with expected post-treatment changes and complica-
tions on surveillance scans can help radiologists to guide pa-
tient management.
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